CLINICAL TRIALS PROFILE FOR ROSIGLITAZONE MALEATE
✉ Email this page to a colleague
All Clinical Trials for ROSIGLITAZONE MALEATE
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00004180 ↗ | Rosiglitazone in Treating Patients With Liposarcoma | Completed | National Cancer Institute (NCI) | Phase 2 | 1999-10-01 | RATIONALE: Rosiglitazone may help liposarcoma cells develop into normal fat cells. PURPOSE: Phase II trial to study the effectiveness of rosiglitazone in treating patients who have liposarcoma. |
| NCT00004180 ↗ | Rosiglitazone in Treating Patients With Liposarcoma | Completed | Dana-Farber Cancer Institute | Phase 2 | 1999-10-01 | RATIONALE: Rosiglitazone may help liposarcoma cells develop into normal fat cells. PURPOSE: Phase II trial to study the effectiveness of rosiglitazone in treating patients who have liposarcoma. |
| NCT00015691 ↗ | Metformin and Rosiglitazone, Alone or in Combination, in HIV-Infected Patients With Insulin and Fat Abnormalities | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | N/A | 1969-12-31 | The purpose of this study is to see whether metformin alone, rosiglitazone alone, or metformin and rosiglitazone together will lower insulin levels in the blood and decrease fat in the abdomen or other parts of the body. Studies have shown that certain anti-HIV medications can cause a number of side effects, including high blood sugar (resulting from the body's failure to use insulin), high insulin, and excess fat build-up in the abdominal area. These side effects are known to increase the risk of heart disease. Metformin and rosiglitazone are 2 drugs that have been shown to lower insulin resistance and lessen abdominal fat in patients who are not HIV-infected. This study will investigate the use of these drugs in HIV-infected patients. |
| NCT00084578 ↗ | Celecoxib and Rosiglitazone in Treating Patients Who Are Undergoing Cystoscopic Surveillance for Early-Stage Noninvasive Carcinoma of the Bladder or Radical Cystectomy for Muscle-Invasive Carcinoma of the Bladder | Withdrawn | National Cancer Institute (NCI) | N/A | 2004-03-01 | RATIONALE: Celecoxib may stop the growth of tumor cells by blocking the enzymes necessary for their growth and by stopping blood flow to the tumor. Rosiglitazone may help tumor cells develop into normal bladder cells. PURPOSE: This randomized clinical trial is studying how well giving celecoxib together with rosiglitazone works in treating patients who are undergoing cystoscopic surveillance (screening) for early-stage noninvasive (carcinoma in situ) carcinoma (cancer) of the bladder or radical cystectomy for muscle-invasive carcinoma (cancer has spread into the muscle layer of bladder tissue) of the bladder. |
| NCT00084578 ↗ | Celecoxib and Rosiglitazone in Treating Patients Who Are Undergoing Cystoscopic Surveillance for Early-Stage Noninvasive Carcinoma of the Bladder or Radical Cystectomy for Muscle-Invasive Carcinoma of the Bladder | Withdrawn | Fox Chase Cancer Center | N/A | 2004-03-01 | RATIONALE: Celecoxib may stop the growth of tumor cells by blocking the enzymes necessary for their growth and by stopping blood flow to the tumor. Rosiglitazone may help tumor cells develop into normal bladder cells. PURPOSE: This randomized clinical trial is studying how well giving celecoxib together with rosiglitazone works in treating patients who are undergoing cystoscopic surveillance (screening) for early-stage noninvasive (carcinoma in situ) carcinoma (cancer) of the bladder or radical cystectomy for muscle-invasive carcinoma (cancer has spread into the muscle layer of bladder tissue) of the bladder. |
| NCT00098852 ↗ | Rosiglitazone in Treating Patients With Locoregionally Extensive or Metastatic Thyroid Cancer | Unknown status | National Cancer Institute (NCI) | Phase 2 | 2004-10-01 | RATIONALE: Drugs such as rosiglitazone may make tumor cells more sensitive to radioactive iodine. PURPOSE: This phase II trial is studying how well rosiglitazone works in treating patients with locoregionally extensive or metastatic thyroid cancer. |
| NCT00098852 ↗ | Rosiglitazone in Treating Patients With Locoregionally Extensive or Metastatic Thyroid Cancer | Unknown status | University of California, San Francisco | Phase 2 | 2004-10-01 | RATIONALE: Drugs such as rosiglitazone may make tumor cells more sensitive to radioactive iodine. PURPOSE: This phase II trial is studying how well rosiglitazone works in treating patients with locoregionally extensive or metastatic thyroid cancer. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for ROSIGLITAZONE MALEATE
Condition Name
Clinical Trial Locations for ROSIGLITAZONE MALEATE
Trials by Country
Clinical Trial Progress for ROSIGLITAZONE MALEATE
Clinical Trial Phase
Clinical Trial Sponsors for ROSIGLITAZONE MALEATE
Sponsor Name
